Skip to Content
Merck
  • Tuneable endogenous mammalian target complementation via multiplexed plasmid-based recombineering.

Tuneable endogenous mammalian target complementation via multiplexed plasmid-based recombineering.

Scientific reports (2015-11-28)
Violeta Beltran-Sastre, Hannah Benisty, Julia Burnier, Imre Berger, Luis Serrano, Christina Kiel
ABSTRACT

Understanding the quantitative functional consequences of human disease mutations requires silencing of endogenous genes and expression of mutants at close to physiological levels. Changing protein levels above or below these levels is also important for system perturbation and modelling. Fast design optimization demands flexible interchangeable cassettes for endogenous gene silencing and tuneable expression. Here, we introduce 'TEMTAC', a multigene recombineering and delivery system for simultaneous siRNA-based knockdown and regulated mutant (or other variant) expression with different dynamic ranges. We show its applicability by confirming known phenotypic effects for selected mutations for BRAF, HRAS, and SHP2.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-BRAF antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution